Start

According to newly released clinical data on Cialis,  PDE5 inhibitor developed by Lilly ICOS LLC for the treatment of erectile dysfunction (ED), men with ED reported a statistically significant improvement in successful intercourse attempts at 24 and 36 hours after taking the drug, compared to placebo.

These and other new findings - including a summary of cardiovascular safety data that showed no increased incidence of cardiovascular events during clinical studies - are being presented at the 97th Annual Meeting of the American Urological Association in Orlando, Florida.

Cialis Period of Effectiveness - Key Study Findings

In a Phase III clinical study designed to evaluate the efficacy of Cialis at specific time points after dosing, 348 men with mild-to-severe ED were randomly assigned to receive Cialis 20 mg (n=175) or placebo (n=173) over approximately an eight-week period. Patients were instructed to attempt intercourse with their partners on four specific occasions: on two occasions at 24 hours after dosing and on two occasions at 36 hours after dosing. The primary endpoint was the percentage of successful sexual intercourse attempts.

“Cialis was statistically superior to placebo in enabling men with ED to have successful intercourse at 24 or 36 hours after taking the drug and showed a consistent effect at both time points,” said Raymond Rosen, Ph.D., study author and director of the Program in Human Sexuality at the University of Medicine and Dentistry of New Jersey and professor of psychiatry, Robert Wood Johnson Medical School, Piscataway, New Jersey. “Also, in this study, the duration of effectiveness did not appear to influence the incidence or severity of side effects.”

In addition, study results show that in secondary measures of efficacy - including ability to penetrate, satisfaction with hardness of erection and overall satisfaction - Cialis was statistically superior to placebo at 24 and 36 hours.

End

This entry was posted on Monday, July 7th, 2008 at 11:58 am and is filed under General Information. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.